AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1824621 — intervention group
Group type: COMPARATOR
Intervention: Patients younger than 60 years
Number of subjects: 167
Study 1824621 — intervention group
Group type: COMPARATOR
Intervention: Patients with reduced peripheral runoff
Number of subjects: 167
Study 1824621 — intervention group
Group type: COMPARATOR
Intervention: Recanalized segments shorter than 7 cm
Number of subjects: 167
Study 1824621 — intervention group
Group type: COMPARATOR
Intervention: Recanalized segments longer than 7 cm
Number of subjects: 167
Study 6362342 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg atenolol
Number of subjects: 52
Study 6362342 — intervention group
Group type: COMPARATOR
Intervention: 100 mg metoprolol
Number of subjects: 52
Study 31521123 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST)
Number of subjects: 1219
Study 28964569 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural diet plus soy-whey blended protein (BP)
Number of subjects: 24
Study 28964569 — intervention group
Group type: COMPARATOR
Intervention: Natural diet only (ND)
Number of subjects: 24
Study 26315978 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement-based care
Number of subjects: 120
Study 26315978 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 120
Study 24237035 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ATRA given 1 hour before and for 7 days following oral typhoid vaccine
Number of subjects: 46
Study 24237035 — intervention group
Group type: COMPARATOR
Intervention: Control interventions (various)
Number of subjects: 46
Study 21968605 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 75
Study 21968605 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxypropyl methylcellulose (HPMC)
Number of subjects: 75
Study 21968605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-in-water emulsion (Emustil unidose; SIFI)
Number of subjects: 75
Study 19326065 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadsparing (QS) approach
Number of subjects: 50
Study 19326065 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (midvastus approach)
Number of subjects: 50
Study 17329652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker outreach plus media-based education
Number of subjects: 1005
Study 17329652 — intervention group
Group type: COMPARATOR
Intervention: Media-based education only
Number of subjects: 1005
Study 15878731 — intervention group
Group type: EXPERIMENTAL
Intervention: HrSz group
Number of subjects: 0
Study 15878731 — intervention group
Group type: COMPARATOR
Intervention: NC group
Number of subjects: 0
Study 12504050 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT) after surgery
Number of subjects: 1058
Study 12504050 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative RT
Number of subjects: 1058
Study 12504050 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive RT
Number of subjects: 1058
Study 12504050 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1058
Study 12504050 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative RT after marginal resections
Number of subjects: 1058
Study 10517767 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocal (20 g/day)
Number of subjects: 20
Study 10517767 — intervention group
Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 20
Study 8915874 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent attenuated cold‐recombinant (CR) vaccine
Number of subjects: 0
Study 8915874 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent subvirion vaccine (TIV)
Number of subjects: 0
Study 8915874 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural influenza virus infection
Number of subjects: 0
Study 8915874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2065463 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg clopamide
Number of subjects: 17
Study 2065463 — intervention group
Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 17
Study 6344309 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 11
Study 6344309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (2.5 mg)
Number of subjects: 11
Study 6344309 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg subcutaneous) after propranolol and pindolol
Number of subjects: 11
Study 31801746 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention programme
Number of subjects: 0
Study 31801746 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 27573420 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, multimedia cervical cancer education program (one-time, low-literacy, delivered in English or Spanish)
Number of subjects: 0
Study 27573420 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study 26908675 — intervention group
Group type: EXPERIMENTAL
Intervention: PARENT (Parent-focused Redesign for Encounters, Newborns to Toddlers)
Number of subjects: 251
Study 26908675 — intervention group
Group type: COMPARATOR
Intervention: Control (usual well-child care)
Number of subjects: 251
Study 26908675 — intervention group
Group type: EXPERIMENTAL
Intervention: PARENT
Number of subjects: 251
Study 24793714 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching video with interactive simulation
Number of subjects: 28
Study 24793714 — intervention group
Group type: COMPARATOR
Intervention: Sham video
Number of subjects: 28
Study 22515882 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal attachment loss
Number of subjects: 45
Study 22515882 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival recession
Number of subjects: 45
Study 20391953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilactase (15 minutes before control H2-LBT)
Number of subjects: 60
Study 20391953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (b.i.d. during 10 days before control H2-LBT)
Number of subjects: 60
Study 20391953 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 minutes before control H2-LBT)
Number of subjects: 60
Study 17290057 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine (5 mg/m2/dose) and Methotrexate (30 mg/m2/dose), administered weekly for 26 weeks and every other week for an additional 26 weeks.
Number of subjects: 28
Study 15811605 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLD subjects
Number of subjects: 22
Study 15811605 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 22
Study 11684174 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 2
Study 11684174 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with idiopathic Parkinson's disease (PDs)
Number of subjects: 2
Study 9628448 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and heparin
Number of subjects: 0
Study 9628448 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel antithrombotic treatments (direct thrombin inhibitors, platelet fibrinogen receptor antagonists, low-molecular-weight heparins)
Number of subjects: 0
Study 7611185 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram-Sure
Number of subjects: 88
Study 7611185 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin susceptibility (5 micrograms and 30 micrograms)
Number of subjects: 88
Study 2093746 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22
Study 2093746 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22
Study 2093746 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study 862493 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision
Number of subjects: 96
Study 862493 — intervention group
Group type: EXPERIMENTAL
Intervention: Marsupialization
Number of subjects: 96
Study 862493 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision without primary closure
Number of subjects: 96
Study 862493 — intervention group
Group type: EXPERIMENTAL
Intervention: Returning to work before wound healed
Number of subjects: 96
Study 862493 — intervention group
Group type: COMPARATOR
Intervention: Resuming work a week after epithelization
Number of subjects: 96
Study 30111291 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic occupational rehabilitation intervention based on Acceptance and Commitment Therapy (3½ weeks duration)
Number of subjects: 212
Study 30111291 — intervention group
Group type: COMPARATOR
Intervention: Benefit work assessment allowance
Number of subjects: 212
Study 30111291 — intervention group
Group type: COMPARATOR
Intervention: Partial sick leave
Number of subjects: 212
Study 30111291 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor economy at baseline
Number of subjects: 212
Study 30111291 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced emotional functioning at baseline
Number of subjects: 212
Study 27030504 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dental pulp stem cell therapy (up to 10 million cells)
Number of subjects: 27
Study 27030504 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dental pulp stem cell therapy (maximum tolerable dose)
Number of subjects: 27
Study 27030504 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dental pulp stem cell therapy combined with 9 weeks of intensive task-specific rehabilitation
Number of subjects: 27
Study 25319228 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan (1 × 160 mg/day)
Number of subjects: 24
Study 25319228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21996661 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral weight-loss program with frequent friend and family support
Number of subjects: 267
Study 21996661 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral weight-loss program with no family support
Number of subjects: 267
Study 21996661 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based behavioral weight-loss program with no friend support
Number of subjects: 267
Study 19200613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/d for 4 weeks
Number of subjects: 22
Study 19200613 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 20 mg/d for 4 weeks
Number of subjects: 22
Study 18680888 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal death condition
Number of subjects: 98
Study 18680888 — intervention group
Group type: COMPARATOR
Intervention: Typical death condition
Number of subjects: 98
Study 18680888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 98
Study 16280943 — intervention group
Group type: EXPERIMENTAL
Intervention: CCLS intervention
Number of subjects: 149
Study 16280943 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 149
Study 12393680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine regimen
Number of subjects: 0
Study 12393680 — intervention group
Group type: COMPARATOR
Intervention: No cyclosporine
Number of subjects: 0
Study 12393680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 0
Study 10579658 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 10
Study 10579658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8904937 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, low-intensity tobacco cessation interventions including counseling by allied professionals, videos, written materials, and telephone calls.
Number of subjects: 0
Study 1791224 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide T (D‐ala1‐peptide T amide) infused at 10(‐7) mol/L
Number of subjects: 14
Study 1791224 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 14
Study 7055177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 75
Study 7055177 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus Gentamicin
Number of subjects: 75
Study 7055177 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics)
Number of subjects: 75
Study 7055177 — intervention group
Group type: COMPARATOR
Intervention: Comparison to controls
Number of subjects: 75
Study 31564512 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg once daily for 6 days
Number of subjects: 28
Study 31564512 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 28
Study 31564512 — intervention group
Group type: COMPARATOR
Intervention: Water without any drug (negative control)
Number of subjects: 28
Study 29663407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-beef containing 25% total fat (25F)
Number of subjects: 12
Study 29663407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-beef containing 18% total fat (18F)
Number of subjects: 12
Study 29663407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground-beef containing 18% total fat (18F) and 25% total fat (25F)
Number of subjects: 12
Study 27769609 — intervention group
Group type: EXPERIMENTAL
Intervention: High cardiorespiratory fitness (CRF) defined as VO2peak >27.5 mL/kg/min in women and >34.4 mL/kg/min in men
Number of subjects: 874
Study 27769609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 874
Study 27769609 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrement in VO2peak (1 metabolic equivalent)
Number of subjects: 874
Study 24856992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 100
Study 24856992 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 100
Study 22223479 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy
Number of subjects: 106
Study 22223479 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 106
Study 20828455 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural drying without a topical regimen
Number of subjects: 150
Study 20828455 — intervention group
Group type: COMPARATOR
Intervention: Cleansing with 95% alcohol after daily bathing
Number of subjects: 150
Study 17845862 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous carbon dioxide insufflations
Number of subjects: 126
Study 17845862 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 126
Study 16219121 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help intervention
Number of subjects: 114
Study 16219121 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 114
Study 14633142 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day)
Number of subjects: 36
Study 14633142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 36
Study 14633142 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 36
Study 10965615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (600,000 units in priming solution, 300,000 units in bypass circuit, 300,000 units daily for 5 days post-surgery)
Number of subjects: 0
Study 10965615 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 0
Study 9047091 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1.7 g daily for 4 days)
Number of subjects: 12
Study 9047091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8418166 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of an RSV subunit vaccine composed primarily of F glycoprotein
Number of subjects: 26
Study 8418166 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 26
Study 3097693 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (3 g)
Number of subjects: 20
Study 3097693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31318264 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 321
Study 31318264 — intervention group
Group type: COMPARATOR
Intervention: School-as-usual control group
Number of subjects: 321
Study 30279397 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil supplement (EPAX: 1600 mg DHA + 400 mg EPA)
Number of subjects: 38
Study 30279397 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 38
Study 28977255 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum stepwise alveolar recruitment associated with PEEP titration (ART strategy)
Number of subjects: 120
Study 28977255 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (ARDSNet strategy)
Number of subjects: 120
Study 26638670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sani Cloth CHG 2% wipes
Number of subjects: 0
Study 26638670 — intervention group
Group type: COMPARATOR
Intervention: Control wipe
Number of subjects: 0
Study 23441920 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical therapy plus azithromycin (AZ-Sca)
Number of subjects: 105
Study 23441920 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical therapy plus placebo (PB-Sca)
Number of subjects: 105
Study 23441920 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival prophylaxis plus azithromycin (AZ-Pro)
Number of subjects: 105
Study 21349204 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-health program (MoodCare) consisting of up to 10 × 30-40 minute structured telephone sessions delivered by registered psychologists, focusing on depression management and lifestyle factors.
Number of subjects: 100
Study 21349204 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) control group receiving standard medical care.
Number of subjects: 100
Study 19055289 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound anesthesia of transcutaneous electrical point stimulation and Remifentanil
Number of subjects: 60
Study 16541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior Exercise (PE) - 10 min at 60% of MAP followed by 4 intervals of 30-s cycling at 100% MAP
Number of subjects: 15
Study 16541377 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior Exercise (PE)
Number of subjects: 15
Study 16541377 — intervention group
Group type: COMPARATOR
Intervention: No Prior Exercise (NPE)
Number of subjects: 15
Study 14601750 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed test for survival-time distributions with dependent censoring
Number of subjects: 0
Study 14601750 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized log-rank test
Number of subjects: 0
Study 14601750 — intervention group
Group type: COMPARATOR
Intervention: Ordinary log-rank test
Number of subjects: 0
Study 11073741 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/day; maximum, 500 mg/day)
Number of subjects: 108
Study 11073741 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (75 mg/kg/day; maximum, 2.5 g/day)
Number of subjects: 108
Study 9189304 — intervention group
Group type: EXPERIMENTAL
Intervention: 3S (multiple set heavy-resistance exercise)
Number of subjects: 8
Study 9189304 — intervention group
Group type: COMPARATOR
Intervention: 1S (single set heavy-resistance exercise)
Number of subjects: 8
Study 8467025 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (50 micrograms/kg)
Number of subjects: 53
Study 8467025 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 53
Study 31909417 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic indication documentation during order entry
Number of subjects: 180
Study 31909417 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic indication documentation for prophylaxis
Number of subjects: 180
Study 31909417 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic indication documentation for empiric antibiotics
Number of subjects: 180
Study 31909417 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic indication documentation for definitive antibiotics
Number of subjects: 180
Study 31909417 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of prescribers regarding documentation burden
Number of subjects: 180
Study 30835308 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention (n=204) including behavioral weight loss treatment, problem-solving therapy, and as-needed antidepressant medications
Number of subjects: 409
Study 30835308 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group (n=205)
Number of subjects: 409
Study 30835308 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated collaborative care intervention (n=204)
Number of subjects: 409
Study 28116579 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention involving four group sessions of motivational interviewing and cognitive behavioural therapy, initiated 4 weeks prior to release.
Number of subjects: 0
Study 28116579 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet and brief verbal intervention at baseline assessment (Control group).
Number of subjects: 0
Study 25323237 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide exposure (10 μg · m(‐3))
Number of subjects: 10377
Study 25323237 — intervention group
Group type: EXPERIMENTAL
Intervention: PM10 exposure (10 μg · m(‐3))
Number of subjects: 10377
Study 25323237 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 exposure (5 μg · m(‐3))
Number of subjects: 10377
Study 24428857 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg body weight, 100 mg/mL)
Number of subjects: 100
Study 24428857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 100
Study 21407047 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of risperidone for the next 32 weeks
Number of subjects: 0
Study 21407047 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone for the next 16 weeks followed by placebo for 16 weeks
Number of subjects: 0
Study 21407047 — intervention group
Group type: COMPARATOR
Intervention: Placebo for the next 32 weeks
Number of subjects: 0
Study 20513572 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 locking screws in the distal row of the plate (Group a)
Number of subjects: 32
Study 20513572 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 locking screws alternately in the distal and proximal rows (Group b)
Number of subjects: 32